Castle biosciences presents case study showcasing the diagnostic performance of diffdx®-melanoma at the college of american pathologists 2022 (cap22) annual meeting

Friendswood, texas--(business wire)---- $cstl #cstl--castle announced a recent poster presentation at cap22 showcasing the performance of its diagnostic gene expression profile test, diffdx®-melanoma.
CSTL Ratings Summary
CSTL Quant Ranking